Potential regulatory roles of miRNA(s) in bone loss and marrow adiposity following methotrexate treatment in rats /
Files
(Published version)
Date
2022
Authors
Zhang, Yali
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
thesis
Citation
Statement of Responsibility
Conference Name
Abstract
Antimetabolite methotrexate (MTX) is a commonly used chemotherapy agent in childhood oncology, which is known to cause bone loss and marrow adiposity in bone marrow, for which the underlying molecular mechanisms are unclear. While small non-coding RNAs (miRNAs) are involved in bone and marrow fat formation, whether and how miRNA(s) plays roles in MTX-induced bone/bone marrow damage are unclear. Current study with in vitro and in vivo studies and using a vast range of techniques has identified that altered expression of miR6315 and miR-542-3p is associated with MTX induced diseases. Findings demonstrate that supplementation of miRNA-6315 or miR-542-3p may be beneficial in preventing MTX-induced bone/fat imbalance.
School/Discipline
University of South Australia. UniSA Clinical and Health Sciences
UniSA Clinical and Health Sciences
UniSA Clinical and Health Sciences
Dissertation Note
Thesis (PhD(Medical Science))--University of South Australia, 2022.
Provenance
Copyright 2022 Yali Zhang
Description
1 ethesis (xviii, 182 pages) : |b colour illustrations, colour charts
Includes bibliographical references
Includes bibliographical references
Access Status
506 0#$fstar $2Unrestricted online access